A novel CD8+ T cell-related gene signature as a prognostic biomarker in hepatocellular carcinoma

Medicine (Baltimore). 2024 Mar 15;103(11):e37496. doi: 10.1097/MD.0000000000037496.

Abstract

CD8+ T cells have great roles in tumor suppression and elimination of various tumors including hepatocellular carcinoma (HCC). Nonetheless, potential prognostic roles of CD8+ T cell-related genes (CD8Gs) in HCC remains unknown. In our study, 416 CD8Gs were identified in HCC, which were enriched in inflammatory and immune signaling pathways. Using The Cancer Genome Atlas dataset, a 5-CD8Gs risk model (KLRB1, FYN, IL2RG, FCER1G, and DGKZ) was constructed, which was verified in International Cancer Genome Consortium and gene expression omnibus datasets. Furthermore, we found that overall survival was independently correlated with the CD8Gs signature, and it was associated with immune- and cancer-related signaling pathways and immune cells infiltration. Finally, drug sensitivity data indicated that 10 chemotherapeutic drugs held promise as therapeutics for HCC patients with high-risk. In conclusion, multi-databases analysis showed that 5-CD8Gs and their signature could be an indicator to predict candidate drugs for HCC therapy.

MeSH terms

  • Biomarkers
  • CD8-Positive T-Lymphocytes
  • Carcinoma, Hepatocellular* / genetics
  • Humans
  • Liver Neoplasms* / genetics
  • Prognosis

Substances

  • Biomarkers